CRANBURY, N.J., May 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2012. Palatin reported a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the quarter ended March 31, 2012, compared to a net loss of $3.8 million, or $(0.17) per basic and diluted share, for the same period in 2011.
The increase in net loss for the quarter ended March 31, 2012, compared to the same period last fiscal year, is mainly attributable to costs related to Palatin's ongoing Phase 2B clinical trial with bremelanotide for Female Sexual Dysfunction (FSD), which commenced in June 2011.
Revenues for the quarter ended March 31, 2012 were $23,996, compared to $61,294 for the quarter ended March 31, 2011. Revenue consists of contract revenue under its collaboration agreement with AstraZeneca.
COSTS AND EXPENSES
Total operating expenses for the quarter ended March 31, 2012 were $6.1 million compared to $2.7 million for the comparable quarter of 2011. The increase in operating expenses for the quarter was primarily due to costs related to Palatin's ongoing Phase 2B clinical trial with bremelanotide for FSD.
Palatin's cash and cash equivalents as of March 31, 2012 were $8.8 million and current liabilities were $3.4 million. Cash and cash equivalents as of June 30, 2011 were $18.9 million with current liabilities of $2.8 million.
Palatin believes, based on its current operating plan, that its cash and cash equivalents at March 31, 2012, will be sufficient to fund its operations through March 31, 2013.
CONFERENCE CALL / WEBCAST
Palatin will host a conference call and webcast on May 14, 2012 at 11:00 a.m. Eastern time to discuss the results of operations in greater detail and an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-888-264-8945 (domestic) or 1-913-312-0724 (international) pass code 8113465. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 8113465. The webcast and telephone replay will be available through May 21, 2012.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons, including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.
PALATIN TECHNOLOGIES, INC.and Subsidiary
Consolidated Statements of Operations
(unaudited)Three Months Ended March 31,Nine Months Ended March 31,2012201120122011REVENUES:Contract$
472,849Grant---846,768Total revenues23,99661,29462,7051,319,617OPERATING EXPENSES:Research and development4,705,6621,722,4329,683,1127,159,634General and administrative1,344,861955,5473,473,9903,226,798Total operating expenses6,050,5232,677,97913,157,10210,386,432Loss from operations(6,026,527)(2,616,685)(13,094,397)(9,066,815)OTHER INCOME (EXPENSE):Investment income5,95518,98228,22972,342Interest expense(1,830)(1,974)(6,650)(5,607)Increase in fair value of warrants-(1,257,691)-(1,257,691)Gain on sale of securities-58,956-119,346Gain (loss) on sale of supplies and equipment1,700(7,466)4,700(5,666)Total other income (expense)5,825(1,189,193)26,279(1,077,276)Loss before income taxes(6,020,702)(3,805,878)(13,068,118)(10,144,091)Income tax benefit--1,068,233637,391NET LOSS$ (6,020,702)$ (3,805,878)$ (11,999,885)$ (9,506,700)Basic and diluted net loss per common share$
(0.65)Weighted average number of common sharesoutstanding used in computing basic and
diluted net loss per common share34,900,59122,832,10934,900,59114,669,131
PALATIN TECHNOLOGIES, INC.and Subsidiary
Consolidated Balance Sheets
2011ASSETSCurrent assets:Cash and cash equivalents$
8,869,639Accounts receivable16,600131,149Prepaid expenses and other current assets673,393261,947Total current assets9,460,24219,262,735Property and equipment, net583,2111,305,331Restricted cash350,000350,000Other assets59,233254,787Total assets$
21,172,853LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations$
34,923Accounts payable557,902496,908Accrued compensation80,728374,094Unearned revenue-46,105Accrued expenses2,776,3911,854,007Total current liabilities3,436,8772,806,037Capital lease obligations25,63842,186Deferred rent81,981132,855Total liabilities3,544,4962,981,078Stockholders' equity:Preferred stock of $.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares as of March 31, 2012 and June 30, 2011, respectively5050Common stock of $.01 par value – authorized 100,000,000 sharesissued and outstanding 34,900,591 shares as of March 31, 2012and June 30, 2011, respectively349,006349,006Additional paid-in capital240,549,126239,832,826Accumulated deficit(233,989,992)(221,990,107)Total stockholders' equity6,908,19018,191,775Total liabilities and stockholders' equity$
|SOURCE Palatin Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved